Advances in clinical chemistry最新文献

Ion mobility spectrometry and ion mobility-mass spectrometry in clinical chemistry. 离子迁移谱法和离子迁移-质谱法在临床化学中的应用。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2024-11-01 DOI: 10.1016/bs.acc.2024.10.003

Kyle E Lira, Jody C May, John A McLean

引用次数: 0

Preface. 前言。

Advances in clinical chemistry Pub Date : 2025-01-01 DOI: 10.1016/S0065-2423(25)00025-3

Gregory S Makowski

引用次数: 0

Metabolomics of nephrotic syndrome. 肾病综合征的代谢组学。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-06-24 DOI: 10.1016/bs.acc.2025.04.004

Shereen M Aleidi, Abeer Malkawi, Hiba Al Fahmawi, Anas M Abdel Rahman

引用次数: 0

Gel electrophoresis-based proteoform separation and analysis. 基于凝胶电泳的蛋白质形态分离与分析。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-05-15 DOI: 10.1016/bs.acc.2025.04.002

Paul Dowling, Kay Ohlendieck

引用次数: 0

From nonexistence to novel applications: Nullomers and related k-mer based concepts in bioinformatics. 从不存在到新的应用：生物信息学中基于k-mer的零分子和相关概念。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-07-11 DOI: 10.1016/bs.acc.2025.06.009

Candace S Y Chan, Ilias Georgakopoulos-Soares

引用次数: 0

Aminopeptidase N (CD13): Bridging physiology, pathology and therapeutic potential. 氨基肽酶N (CD13)：连接生理、病理和治疗潜力。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-08-25 DOI: 10.1016/bs.acc.2025.07.002

Gabriel C Nwokolo, Robert A Falconer, Francis M Barnieh

引用次数: 0

Lupus nephritis: Biomarkers. 狼疮性肾炎：生物标志物。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2024-11-07 DOI: 10.1016/bs.acc.2024.10.002

Chrisanna Dobrowolski, Shu Min Lao, Fadi Kharouf, Paula Parnizari Croci, Joan Wither, Dafna D Gladman, Laura Whitall Garcia, Arenn Jauhal, Zahi Touma

引用次数: 0

Coagulopathy prediction in traumatic brain injury. 外伤性脑损伤凝血功能预测。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-02-10 DOI: 10.1016/bs.acc.2025.01.003

Evangelos Kalogirou, Spyridon Voulgaris, George A Alexiou

{"title":"Coagulopathy prediction in traumatic brain injury.","authors":"Evangelos Kalogirou, Spyridon Voulgaris, George A Alexiou","doi":"10.1016/bs.acc.2025.01.003","DOIUrl":"10.1016/bs.acc.2025.01.003","url":null,"abstract":"Traumatic brain injury (TBI) represents a significant public health concern. Besides the initial primary injury, a defining point of TBI is causing secondary, delayed damage through inflammatory biochemical processes. Among the complications arising from this inflammatory response, coagulopathy emerges as a critical concern. With an overall prevalence of 32.7 %, TBI-induced coagulopathy significantly contributes to increased mortality rates and unfavorable patient outcomes, through its clinical manifestations, such as progressive hemorrhagic injury (PHI). This chapter investigates biomarkers capable of accurately detecting coagulopathy and PHI in TBI, evaluating their potential utility based on statistical evidence from various studies and exploring their possible association in the biochemical processes guiding or following TBI-induced coagulopathy. Notably, glucose emerges as a standout candidate, exhibiting a sensitivity of 91.5 % and specificity of 87.5 % for predicting coagulopathy. Furthermore, interleukin-33, with a sensitivity of 93.3 % and specificity of 66.7 %, and galectin-3, with a sensitivity of 67.7 % and specificity of 85.5 %, are promising for PHI. Despite these encouraging findings, significant efforts remain necessary to translate biomarker diagnostic utility into clinical practice effectively. Further research and validation studies are imperative to elucidate the intricate biochemical processes underlying TBI-induced coagulopathy and to refine the clinical application of biomarkers for improved patient management and outcomes in real-world settings.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"126 ","pages":"199-231"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MDDB: A public databank of host microRNAs in Tuberculosis diagnosis. MDDB：结核诊断中宿主microrna的公共数据库。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-06-10 DOI: 10.1016/bs.acc.2025.04.006

Piyush Agrawal, Aditya Upadhyay, Ravindra Kumar Chauhan, Awanish Kumar

{"title":"MDDB: A public databank of host microRNAs in Tuberculosis diagnosis.","authors":"Piyush Agrawal, Aditya Upadhyay, Ravindra Kumar Chauhan, Awanish Kumar","doi":"10.1016/bs.acc.2025.04.006","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.04.006","url":null,"abstract":"Tuberculosis (TB) remains a major global health challenge due to its high mortality rate. Several factors contribute significantly including delayed diagnosis, emergence of drug resistance, and biofilm formation. Although various diagnostic methods are available for TB, such as sputum smear microscopy, culture techniques, and real-time polymerase chain reaction (PCR). They have notable limitations, including false positives and negatives, timeliness, and high cost. Therefore, there is an urgent need for an early and accurate diagnostic approach to control the infection. MicroRNA (miRNA)-based diagnostics have emerged as a promising alternative, offering the potential for earlier detection and reduced false-positivity. However, this field is still in development and requires specialized tools to accelerate miRNA research, streamline the process, and facilitate the creation of innovative diagnostic methods. To address this need, the MicroRNA Disease Databank (MDDB) was developed as a centralized platform providing extensive miRNA-related information. Freely accessible at https://mddb.nitrr.ac.in/., MDDB offers comprehensive details on miRNA locations, associated disease characteristics, probe sequences, and molecular mechanisms. This resource aims to support the development of novel miRNA-based diagnostic biomarkers. This article provides an in-depth overview of the MDDB tool, highlighting its construction, features, and accessibility. Currently, MDDB focuses on host miRNAs relevant to TB, allowing researchers to quickly access critical miRNA data. By leveraging this resource, researchers will potentially accelerate the development of effective diagnostic biomarkers for TB and other chronic diseases in the future.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"127 ","pages":"221-253"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging markers in celiac disease. 乳糜泻的新标志物。

Advances in clinical chemistry Pub Date : 2025-01-01 Epub Date: 2025-07-11 DOI: 10.1016/bs.acc.2025.06.010

Sajjad Bakhtiari, Mohammad Rostami-Nejad

{"title":"Emerging markers in celiac disease.","authors":"Sajjad Bakhtiari, Mohammad Rostami-Nejad","doi":"10.1016/bs.acc.2025.06.010","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.06.010","url":null,"abstract":"Celiac disease (CD) is a chronic autoimmune disorder triggered by gluten ingestion in genetically predisposed individuals. Current diagnostic methods rely on serological markers, histological examination of duodenal biopsies, and HLA genotyping. However, these approaches have limitations. Advancements in serology have introduced novel autoantibodies beyond tissue transglutaminase (tTG) and endomysial antibodies (EMA), such as neo-epitope tTG and transglutaminase isoforms. Genetic and epigenetic markers, including non-HLA risk alleles, DNA methylation patterns, and non-coding RNAs, provide deeper insights into CD susceptibility. Additionally, cytokine profiling and immune response markers, such as pro-inflammatory and anti-inflammatory cytokines, chemokines, and adhesion molecules, reflect disease pathophysiology and may serve as diagnostic and prognostic tools. Gut microbiota alterations and metabolomic signatures further highlight immune dysregulation and metabolic changes in CD, offering potential biomarkers for diagnosis and disease monitoring. Protein and peptide biomarkers, including intestinal fatty acid-binding protein (I-FABP), plasma citrulline, and regenerating gene Ia (REG Ia), provide insights into intestinal damage and mucosal healing. Furthermore, emerging technologies such as point-of-care testing (POCT) and nanoparticle-based assays enhance diagnostic precision. The objective of this chapter is to provide a comprehensive review of emerging biomarkers and novel technologies that can improve the diagnosis and monitoring of CD. Emphasis is placed on advances in serology, genetic and epigenetic profiling, immune and cytokine markers, metabolomics, and gut microbiota analysis. The chapter also discusses the integration of multi-omics approaches and artificial intelligence-driven analysis as future directions for refining diagnostic accuracy and enabling personalized disease management.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"129 ","pages":"123-189"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0